“…Especially in pharmaceutical development, collective creativity depends on tight control and clear objectives as well as experimentation, surprise, and uncertainty (Dougherty, 2015; Dunne & Dougherty, 2015; Styhre & Sundgren, 2011; Sundgren & Styhre, 2003). Accordingly, the relation between creativity and constraint is typically conceptualized as an inverted U‐shape: too much as well as too little constraint hinders collective creativity (Acar, Tarakci, & van Knippenberg, 2018; Cirella, 2016; Rosso, 2014). Therefore, management scholars suggest balancing constraints, meaning to establish an optimized and middle ground “sweet spot” of constraints, in order to organize for creative output (Chen, 2012; Cirella, 2016; Davis & Scase, 2000; Gilson, Mathieu, Shalley, & Ruddy, 2005; Lampel et al, 2014; Rosso, 2014; Shalley & Gilson, 2017).…”